Safety of DEHP: role of the bureau of biologics. by Fratantoni, J C
Commentary
Environmental Health Perspectives
Vol. 45, pp. 143-144, 1982
Safety of DEHP: Role of the Bureau of
Biologics
by Joseph C. Fratantoni*
The position of the Bureau of Biologics (BoB)
relative to the issue at hand is unique on several
counts. First, Bureau ofBiologics is formally inter-
ested in the phthalate issue only in connection with
containers forbloodandbloodproducts. Theauthor-
ity to regulate the nature ofsuch containers derives
from specific regulations. For example, regarding
plasma, 21 CFR, Section 648.68(b) states: "Final
containers and their components shall not interact
with the plasma contents under conditions of stor-
age and use so as to alterthe safety, quality, purity
or potency ofthe plasma."
Second, the subjects involved are exposed to the
highest doses of DEHP, and it is delivered via the
intravenous route. Most of these subjects are
patients undergoing treatment, although the in-
creased interest in pheresis procedures will result
in similar exposure for more and more normal
donors.
Finally, BoB has considered the DEHP in vinyl
plastics to be a problem for anumber ofyears. That
is, we have been aware that DEHP, a biologically
active material, was leached by blood and plasma in
considerable quantities from the PVC bags. We
were also aware that the available data on toxicity
did not support a regulatory demand for immediate
change. Members of the blood, banking community
were similarly concerned, and this concern was
shared by the manufacturers of blood bags, as
indicated by the considerable research expendi-
tures dedicated tothe quest for asubstitute plastic.
At BoB the concerns which derived from the
presence of DEHP were balanced by an apprecia-
tion ofthe need for a flexible container. The entire
science of blood component preparation in a sealed
system is dependent upon a flexible container. The
Bureau of Biologics would therefore consider that
reversion to a system based on glass bottles is not a
viable alternative.
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As far as actions that have beentaken and will be
taken, I would like to refer to the interesting
dialogue at this conference between Drs. Peck and
Kevy regarding the ability to show that any ofthe
deposition of DEHP in mammalian organs led to
demonstrable toxicity. I believe that both Drs.
Peck and Kevy would agree that another question
is appropriate andthat is, rather than asking, "Is it
toxic?" the question might be, "Is it possible to
demonstrate toxicity in the clinical situation?" I
further believe they would both agree that, given
the difficulties of clinical investigation, it is not
possible to answer that question. So, for the
immediate future, the BoBwili not await adefinitive
answer to the toxicity question, but will address
other approaches to the problem.
We are aware that there is some concern about
the rapidity with which submissions are reviewed
and approved. Accordingly, we havealreadyunder-
gone some discussion, namely, blood and blood
product containers, both dry and with anticoagu-
lant. Specifically, after a period ofabout two years
of investigating and holding conferences on the
subjectoftestingbloodplatelets, wehavesimplified
the procedures which were being demanded ofthe
manufacturer for obtaining approval of a container
used for storage of platelets. It had been the
opinion ofmany in the community that this particu-
lar type oftesting was the most onerous. We have
developed a new set of guidelines which are avail-
able to any interested person and can be obtained
by writing to the Director, Bureau of Biologics.
We will encourage accumulation of data on the
content of DEHP in various blood products and
hope, some time in the foreseeable future, to be
able to encourage the development ofguidelines for
blood banking practice. Since we need a flexible
bag, and the currently available systems have large
amounts ofleachable plasticizers, we would hope to
limit exposure by some simple expedient such as
using the shortest storage time possible for those
components where this is practical. Knowledge of
the DEHP content of various components, corre-144
lated with the conditions for their preparation and
storage, should suggest a variety of maneuvers
which would decrease patient exposure to infused
DEHP.
We certainly agree that more fundamental data
regarding carcinogenicity of DEHP are needed.
Given the problems with the assay system, the
variations in the literature stated, and species
differences that we have heard about, we believe
that any quantitative assessments of risk are pre-
mature at this time. We have been opposed to
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disseminating such details to patients, such as
hemophiliacs and leukemics, whom we feel are
sufficiently burdened, and need not be concerned
with questionable numbers at this time.
Finally, regarding the question that was asked in
the previous session about atimetable foraction. In
addition to what has been said, I can only state that
the Bureau of Biologics will take further action
when we feel that there is a consensus within the
scientific community that it is time to do so. At this
time, we do not feel that there is such a consensus.